Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass

Yuta Yokoyama, Kazuaki Matsumoto, Kazuro Ikawa, Erika Watanabe, Hiroyuki Yamamoto, Yutaka Imoto, Norifumi Morikawa, Yasuo Takeda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Antibiotic concentrations must be maintained at an adequate level throughout cardiovascular surgery to prevent surgical site infection. This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB). The total plasma concentrations of ampicillin were monitored in 8 patients after ampicillin (1 g)-sulbactam (0.5 g) administration via initial intravenous infusion and subsequent CPB priming. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin. The mean values for the volume of distribution, elimination rate constant, elimination half-life, and total clearance of ampicillin were 15.8±4.1 L, 0.505±0.186 h-1, 1.52±0.47 h, and 7.72±2.72 L/h, respectively. When ampicillin (1 g)-sulbactam (0.5 g) was intravenously administered every 3, 4, 6, and 12 h after the start of CPB, the predicted free trough plasma concentrations of ampicillin were 15.20, 8.25, 2.74, and 0.13 μg/mL, respectively. Therefore, an every-6-h regimen was needed to maintain the free ampicillin concentration at more than 2 μg/mL during cardiovascular surgery with CPB. We suggest that the dose and dosing interval for ampicillin-sulbactam should be adjusted to optimize the efficacy and safety of treatment, according to the minimum inhibitory concentrations for methicillin-sensitive Staphylococcus aureus isolates at each institution.

Original languageEnglish
Pages (from-to)1817-1821
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume38
Issue number11
Publication statusPublished - 2015 Nov 1
Externally publishedYes

Fingerprint

Ampicillin
Cardiopulmonary Bypass
Pharmacokinetics
Sulbactam
Surgical Wound Infection
Methicillin
Antibiotic Prophylaxis
Microbial Sensitivity Tests
sultamicillin
Intravenous Infusions
Half-Life
Staphylococcus aureus
Anti-Bacterial Agents
Safety

Keywords

  • Ampicillin
  • Cardiopulmonary bypass
  • Cardiovascular surgery
  • Prophylaxis
  • Sulbactam

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology

Cite this

Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass. / Yokoyama, Yuta; Matsumoto, Kazuaki; Ikawa, Kazuro; Watanabe, Erika; Yamamoto, Hiroyuki; Imoto, Yutaka; Morikawa, Norifumi; Takeda, Yasuo.

In: Biological and Pharmaceutical Bulletin, Vol. 38, No. 11, 01.11.2015, p. 1817-1821.

Research output: Contribution to journalArticle

Yokoyama, Yuta ; Matsumoto, Kazuaki ; Ikawa, Kazuro ; Watanabe, Erika ; Yamamoto, Hiroyuki ; Imoto, Yutaka ; Morikawa, Norifumi ; Takeda, Yasuo. / Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass. In: Biological and Pharmaceutical Bulletin. 2015 ; Vol. 38, No. 11. pp. 1817-1821.
@article{7a0ef82599444aaea72f0f6aa5e808af,
title = "Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass",
abstract = "Antibiotic concentrations must be maintained at an adequate level throughout cardiovascular surgery to prevent surgical site infection. This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB). The total plasma concentrations of ampicillin were monitored in 8 patients after ampicillin (1 g)-sulbactam (0.5 g) administration via initial intravenous infusion and subsequent CPB priming. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin. The mean values for the volume of distribution, elimination rate constant, elimination half-life, and total clearance of ampicillin were 15.8±4.1 L, 0.505±0.186 h-1, 1.52±0.47 h, and 7.72±2.72 L/h, respectively. When ampicillin (1 g)-sulbactam (0.5 g) was intravenously administered every 3, 4, 6, and 12 h after the start of CPB, the predicted free trough plasma concentrations of ampicillin were 15.20, 8.25, 2.74, and 0.13 μg/mL, respectively. Therefore, an every-6-h regimen was needed to maintain the free ampicillin concentration at more than 2 μg/mL during cardiovascular surgery with CPB. We suggest that the dose and dosing interval for ampicillin-sulbactam should be adjusted to optimize the efficacy and safety of treatment, according to the minimum inhibitory concentrations for methicillin-sensitive Staphylococcus aureus isolates at each institution.",
keywords = "Ampicillin, Cardiopulmonary bypass, Cardiovascular surgery, Prophylaxis, Sulbactam",
author = "Yuta Yokoyama and Kazuaki Matsumoto and Kazuro Ikawa and Erika Watanabe and Hiroyuki Yamamoto and Yutaka Imoto and Norifumi Morikawa and Yasuo Takeda",
year = "2015",
month = "11",
day = "1",
language = "English",
volume = "38",
pages = "1817--1821",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of prophylactic ampicillin-sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass

AU - Yokoyama, Yuta

AU - Matsumoto, Kazuaki

AU - Ikawa, Kazuro

AU - Watanabe, Erika

AU - Yamamoto, Hiroyuki

AU - Imoto, Yutaka

AU - Morikawa, Norifumi

AU - Takeda, Yasuo

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Antibiotic concentrations must be maintained at an adequate level throughout cardiovascular surgery to prevent surgical site infection. This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB). The total plasma concentrations of ampicillin were monitored in 8 patients after ampicillin (1 g)-sulbactam (0.5 g) administration via initial intravenous infusion and subsequent CPB priming. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin. The mean values for the volume of distribution, elimination rate constant, elimination half-life, and total clearance of ampicillin were 15.8±4.1 L, 0.505±0.186 h-1, 1.52±0.47 h, and 7.72±2.72 L/h, respectively. When ampicillin (1 g)-sulbactam (0.5 g) was intravenously administered every 3, 4, 6, and 12 h after the start of CPB, the predicted free trough plasma concentrations of ampicillin were 15.20, 8.25, 2.74, and 0.13 μg/mL, respectively. Therefore, an every-6-h regimen was needed to maintain the free ampicillin concentration at more than 2 μg/mL during cardiovascular surgery with CPB. We suggest that the dose and dosing interval for ampicillin-sulbactam should be adjusted to optimize the efficacy and safety of treatment, according to the minimum inhibitory concentrations for methicillin-sensitive Staphylococcus aureus isolates at each institution.

AB - Antibiotic concentrations must be maintained at an adequate level throughout cardiovascular surgery to prevent surgical site infection. This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB). The total plasma concentrations of ampicillin were monitored in 8 patients after ampicillin (1 g)-sulbactam (0.5 g) administration via initial intravenous infusion and subsequent CPB priming. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin. The mean values for the volume of distribution, elimination rate constant, elimination half-life, and total clearance of ampicillin were 15.8±4.1 L, 0.505±0.186 h-1, 1.52±0.47 h, and 7.72±2.72 L/h, respectively. When ampicillin (1 g)-sulbactam (0.5 g) was intravenously administered every 3, 4, 6, and 12 h after the start of CPB, the predicted free trough plasma concentrations of ampicillin were 15.20, 8.25, 2.74, and 0.13 μg/mL, respectively. Therefore, an every-6-h regimen was needed to maintain the free ampicillin concentration at more than 2 μg/mL during cardiovascular surgery with CPB. We suggest that the dose and dosing interval for ampicillin-sulbactam should be adjusted to optimize the efficacy and safety of treatment, according to the minimum inhibitory concentrations for methicillin-sensitive Staphylococcus aureus isolates at each institution.

KW - Ampicillin

KW - Cardiopulmonary bypass

KW - Cardiovascular surgery

KW - Prophylaxis

KW - Sulbactam

UR - http://www.scopus.com/inward/record.url?scp=84946913068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946913068&partnerID=8YFLogxK

M3 - Article

C2 - 26521833

AN - SCOPUS:84946913068

VL - 38

SP - 1817

EP - 1821

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 11

ER -